title: Anaplastic lymphoma kinase in human cancer.
abstract: The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. This review will discuss our current understanding of ALK in human cancer and the implication of recent results for treatment.
authors.affiliation: Department of Molecular Biology, Umea University, Umea, Sweden.
authors.forename: Christina
authors.initials: C
authors.lastname: Schonherr
authors.forename: Bengt
authors.initials: B
authors.lastname: Hallberg
authors.forename: Ruth
authors.initials: R
authors.lastname: Palmer
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000201:enzymology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases